Cyclerion Therapeutics, Inc.

Cyclerion Therapeutics, Inc.

Biotechnology • Healthcare • Cambridge, MA, United States • CYCN (NCM)

Cyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases serious diseases with novel sGC stimulators in both the central nervous system (CNS) and the periphery. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to treat cardiovascular diseases; and Praliciguat, a systemic sGC stimulator for the treatment of rare kidney disease. It has a license agreement with Akebia to develop, manufacture, medical affair, and commercializes Praliciguat and other related products. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

857 327 8778 245 First Street, Riverview II, Cambridge, MA 02142, United States

Stock Performance (90 Days)

Data through Dec 29, 2025
Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

Insider Stock Buying Reaches US$525.0k On Cyclerion Therapeutics - Yahoo Finance
Yahoo Finance • Nov 11
Why Did Cyclerion Therapeutics Stock Surge Nearly 50% After-Hours Today? - Stocktwits
Stocktwits • Sep 24
Cyclerion Therapeutics’ Licence Move: Boost or Bust? - StocksToTrade
StocksToTrade • Sep 24
Cyclerion stock soars after MIT licensing deal to relaunch company - Investing.com
Investing.com • Sep 23
Cyclerion Secures MIT License for Treatment-Resistant Depression Drug | CYCN Stock News - Stock Titan
Stock Titan • Sep 23

Other Biotechnology Companies

View All →
CODEXIS, INC. logo Codexis, Inc.
1 layoff tracked
$144.5M market cap
VERTEX PHARMACEUTICALS INC / MA logo Vertex Pharmaceuticals Inc. / MA
$118.68B market cap
REGENERON PHARMACEUTICALS, INC. logo Regeneron Pharmaceuticals, Inc.
$82.72B market cap
ALNYLAM PHARMACEUTICALS, INC. logo Alnylam Pharmaceuticals, Inc.
$52.92B market cap
ARGENX SE logo Argenx SE
$52.62B market cap
INSMED Inc logo Insmed Inc.
$37.61B market cap

Frequently Asked Questions

Has Cyclerion Therapeutics, Inc. had layoffs?
No layoff events have been recorded for Cyclerion Therapeutics, Inc. in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.
How many employees does Cyclerion Therapeutics, Inc. have?
Cyclerion Therapeutics, Inc. has approximately 1 employees.
What industry is Cyclerion Therapeutics, Inc. in?
Cyclerion Therapeutics, Inc. operates in the Biotechnology industry, within the Healthcare sector.
Is Cyclerion Therapeutics, Inc. a publicly traded company?
Yes, Cyclerion Therapeutics, Inc. is publicly traded under the ticker symbol CYCN on the NCM. The company has a market capitalization of approximately $0.00 billion.
Where is Cyclerion Therapeutics, Inc. headquartered?
Cyclerion Therapeutics, Inc. is headquartered in Cambridge, MA, United States at 245 First Street, Riverview II, Cambridge, MA 02142, United States.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.